Erythropoietin gene therapy - Oxford BioMedicaAlternative Names: Repoxygen
Latest Information Update: 13 Aug 2003
At a glance
- Originator Oxford BioMedica
- Class Antianaemics; Gene therapies; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia